NASDAQ$IRON
Disc Medicine Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Gemini Therapeutics reported financial results and provided a business update.
Gemini Therapeutics reported a net loss of $16.4 million, or $0.38 per share, for the second quarter ended June 30, 2021. The company's research and development expenses totaled $10.8 million, and general and administrative expenses were $5.5 million. As of June 30, 2021, Gemini held $167.5 million in cash.
- Initial data from Phase 2a study in geographic atrophy demonstrated GEM103's ability to regulate complement and showed a differentiated safety profile.
- Enrollment completed in Phase 2a study of GEM103 in wet AMD, with six-month data expected by year-end.
- A randomized, sham-controlled clinical trial to evaluate GEM103's ability to limit geographic atrophy is planned for 1H 2022.
- Initial study data highlighted GEM103’s generally favorable safety and tolerability profile.
Headline financials
Revenue & EPS history
Disc Medicine · Revenue · Quarterly
$0
Forward guidance
Gemini Therapeutics is advancing GEM103 for genetically defined AMD and planning a sham-controlled study for geographic atrophy in 1H 2022.
Tailwinds
- GEM103 demonstrated ability to regulate complement.
- GEM103 showed a differentiated safety profile.
- Phase 2a study enrollment completed for wet AMD.
- Six-month data for wet AMD study expected by year-end.
- Sham-controlled trial planned for geographic atrophy in 1H 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2021
-0.4%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+3.9%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+14.6%
Q3 2021
Best reaction
-12.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.3% | -3.8% | -10.2% | |
| Q3 2025 | -1.6% | -2.5% | +5.6% | |
| Q2 2025 | -3.4% | +0.1% | +3.0% | |
| Q1 2025 | +2.3% | +3.8% | +14.1% | |
| Q4 2024 | +0.1% | +1.6% | -3.9% | |
| Q3 2024 | -5.3% | -10.7% | -3.5% | |
| Q1 2024 | +3.5% | +8.5% | +33.3% | |
| Q4 2023 | -8.7% | -9.2% | -56.8% | |
| Q3 2023 | +1.7% | +8.1% | +27.8% | |
| Q2 2023 | +0.3% | +1.9% | -1.2% | |
| Q1 2023 | +0.6% | +1.8% | +47.6% | |
| Q4 2022 | -0.6% | +0.7% | +48.4% | |
| Q3 2022 | -0.6% | -4.7% | -2.4% | |
| Q2 2022 | -12.4% | -10.9% | -31.8% | |
| Q1 2022 | +3.6% | +10.1% | +8.6% | |
| Q4 2021 | -3.2% | -7.7% | -11.0% | |
| Q3 2021 | +14.6% | -5.6% | -12.6% | |
| Q2 2021 | +0.2% | -12.8% | +15.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro